Sector News

GlobeImmune CEO steps down as partnership with Gilead fizzles

November 21, 2016
Life sciences

GlobeImmune has been struggling for some time, and its Nov. 18 updates effectively ward off investor hopes for a turnaround in the near term.

In June 2015, the company initiated a strategic review in the hopes of finding a transaction to lift the business. In conjunction with that announcement, GlobeImmune cut the bulk of its workforce to provide enough cash to continue operations.

The review, which ended earlier this year, never yielded any transaction.

The biopharma has kept mostly quiet since July, when it delisted from the NASDAQ and moved over to the OTC Pink stock market. In its last quarterly filing with the Securities and Exchange Commission, GlobeImmune reported $8.7 million in cash and cash equivalents as of March 31, which comprised 89% of its total assets. GlobeImmune also reported $7.6 million in liabilities.

In a release, the company cited “ongoing listing, legal, administrative and additional accounting costs,” an “inordinate amount of executive time and Company resources consumed in regulatory compliance obligations,” and a “lack of investor interest as shown in the low daily trading volumes of the Common Stock on NASDAQ,” as reasons for the delisting.

From Gilead’s end, the Food and Drug Administration’s approval of hep B drug Vemlidy earlier this month likely made it easier to separate ties with GlobeImmune. Still, the pharmaceutical heavyweight has seen revenues from its antiviral portfolio shrink as of late. Global sales of those products shrunk more than 10% — from $7.7 billion to $6.8 billion — between the third quarter of 2015 and the same period this year.

GlobeImmune did not disclose any potential replacements for Rodell.

Company shares traded at 50 cents Friday morning, down 28%.

By Jacob Bell

Source: BioPharmaDive

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.